Ads
related to: tyrosine kinase inhibitors- GIST Resistance
Learn more about the complexity of
GIST and a treatment option.
- Patient Education
A patient and care partners guide
with treatment information.
- Distribution Fact Sheet
A resource with info about
treatment distribution.
- Request Educational Info
Request patient educational
materials and more.
- Patient Financial Help
Resources may be available
for your patients.
- Patient Starter Kit
Help your patients get started
with helpful tools & resources.
- GIST Resistance
Search results
Ponatinib superior to imatinib in Ph+ ALL - Nature Reviews Clinical Oncology
Nature· 1 day agoBCR–ABL1 tyrosine kinase inhibitors, in combination with chemotherapy and/or steroids, are the standard-of-care therapy for patients ...
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug...
WFRV 5 Green Bay· 6 days agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its ...
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 6 days ago... data include an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA®), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus pembrolizumab (KEYTRUDA®), Merck's...
Conference MDAngle: ASCO 2024 Chronic Myeloid Leukemia
Medscape· 7 days agoDr Jorge Cortes previews compelling studies at ASCO 2024 in CML, including updates on OPTIC's 4-year...
Exploring the pathways of drug repurposing and Panax ginseng treatment mechanisms in chronic heart...
Nature· 2 days agoChronic Heart Failure (CHF) is a significant global public health issue, with high mortality and morbidity rates and associated costs. Disease modules, which are collections of disease-related ...
MD Anderson Research Highlights: ASCO 2024 Special | Newswise
Newswise· 7 days agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of...
Digital Journal· 6 days agoOral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task forceTop line results imminent ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 6 days agoPreliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic
Tenax Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($1.72) Per Share (NASDAQ:TENX)
ETF DAILY NEWS· 6 days agoTenax Therapeutics, Inc. (NASDAQ:TENX – Free Report) – Equities researchers at Zacks Small Cap cut their Q2 2024 earnings per share (EPS) estimates for shares of Tenax Therapeutics in a report ...
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - Cogent Biosciences...
Benzinga· 6 days agoCogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial ...